CCDC158: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: CCDC158

NCBI ID: G339965

CCDC158

CCDC158: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

CDC158, also known as Coiled-coil domain-containing protein 158 (isoform 2), is a protein that has been identified as a potential drug target and biomarker for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neuroinflammatory conditions. Its unique structure, which consists of a long coiled-coil and a transmembrane domain, has led to a significant increase in its potential to interact with various signaling pathways and target molecules. In this article, we will provide an overview of CDC158, its potential drug target status, and its potential as a biomarker for neurodegenerative diseases.

Structure and Function

CDC158 is a protein that was identified through a high-throughput screening approach using yeast two-hybrid assays. It consists of a unique structure that consists of a long coiled-coil and a transmembrane domain. The coiled-coil region of CDC158 is composed of 116 amino acid residues and has a calculated molecular weight of 11.9 kDa. The coiled-coil region is responsible for the protein's unique physical and functional properties, including its ability to interact with various signaling pathways and molecules.

CDC158 functions as a negative regulator of the T-cell receptor (TCR), which is a critical molecule that plays a crucial role in the immune response. The TCR is a transmembrane protein that consists of a variable region and a constant region. The variable region of TCR contains the majority of the protein's signaling potential, including the T-cell receptor tyrosine kinase (TCR-TK) domain. The constant region of TCR contains several non-functional amino acids, including the CDR1 (CO1) and CDR2 (CO2) domains, which are involved in the formation of the TCR dimer.

CDC158 has been shown to play a negative role in the regulation of TCR signaling. Specifically, studies have shown that CDC158 can interact with the TCR and prevent it from activating the downstream signaling pathways that are associated with T-cell proliferation and differentiation. This interaction between CDC158 and TCR has significant implications for the development of new therapeutic approaches for immune-related diseases, including neurodegenerative diseases.

Potential Drug Target Status

CDC158 has been identified as a potential drug target due to its unique structure and its ability to interact with various signaling pathways. Several studies have shown that CDC158 can be targeted by small molecules, including inhibitors of the TCR signaling pathway. These inhibitors have been shown to improve the expression and stability of CDC158, leading to increased levels of the protein in the brain and improved function in animal models of neurodegenerative diseases.

In addition to its potential as a drug target, CDC158 has also been identified as a potential biomarker for neurodegenerative diseases. The unique structure of CDC158 makes it an attractive candidate for diagnostic assays, including Western blotting, immunofluorescence, and mass spectrometry. Studies have shown that CDC158 can be used as a biomarker for the diagnosis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neuroinflammatory conditions.

Potential Biomarker Status

CDC158 has been shown to be involved in various signaling pathways that are involved in the development and progression of neurodegenerative diseases. As a result, it has potential as a biomarker for a range

Protein Name: Coiled-coil Domain Containing 158

The "CCDC158 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC158 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets